### Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024

Data Lock Date: 23-May-2024 18:30:03

Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine

Analysis Print:

All UK spontaneous suspected Adverse Drug Reaction (ADR) reports associated with the COVID-19 Vaccine

AstraZeneca (Batch 4120Z002)

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
Blood disorders	1001	
Anaemia deficiencies		
Iron deficiency anaemia	1	ıl o
Anaemias NEC		
Anaemia	2	2 0
Bleeding tendencies		
Increased tendency to bruise	1	ıl o
Spontaneous haematoma	1	ıl o
Coagulopathies		
Antiphospholipid syndrome	1	ı  o
Coagulopathy	1	ı  o
Eosinophilic disorders		
Eosinophilia	1	ı  o
Haematological disorders		
Mast cell activation syndrome	2	0
Leukocytoses NEC		
Neutrophilia	1	ı  o
Lymphatic system disorders NEC		
Lymph node pain	15	5 0
Lymphadenitis	1	1 0
Lymphadenopathy	147	7 0
Neutropenias		
Agranulocytosis	1	ı  0
Neutropenia	1	1 0
Purpuras (excl thrombocytopenic)		
Purpura non-thrombocytopenic	1	1 0
Red blood cell abnormal findings NEC		
Macrocytosis	1	1 0
Thrombocytopenias		
Immune thrombocytopenia	3	
Thrombocytopenia	12	0
Thrombocytopenic purpura	1	I 0
Thrombosis with thrombocytopenia syndrome	. 2	2 0
Thrombocytoses		
Thrombocytosis	1	ı  o
Blood disorders SOC TOTAL	197	7 0

### Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Farliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Earliest Reaction Date: 07-Feb-2018	MedDRA Version: MedDRA 27.0	
Reaction Name	Total	Fatal
Cardiac disorders		
Cardiac conduction disorders		
Atrioventricular block complete		1 0
Trifascicular block		0
Cardiac disorders NEC		
Cardiac disorder		2 0
Cardiac ventricular thrombosis		0
Cardiac signs and symptoms NEC		
Cardiac discomfort		1 0
Cardiovascular symptom		1 0
Palpitations	157	
Cardiomyopathies		
Cardiomyopathy		1 0
Dilated cardiomyopathy		1 0
Coronary artery disorders NEC		
Arteriosclerosis coronary artery		0
Heart failures NEC		
Cardiac failure		2 0
Ischaemic coronary artery disorders		
Acute myocardial infarction		1 2
Angina pectoris		1 2 7 0
Arteriospasm coronary		ı ő
Myocardial infarction	2.	0
Myocardial ischaemia		il ő
Myocardial disorders NEC		
Cardiac sarcoidosis	,	1 0
Cardiomegaly		i o
Left ventricular dysfunction		il ő
Ventricular hypertrophy		
Noninfectious myocarditis		
Myocarditis	,	5 0
Myopericarditis		2 0
Noninfectious pericarditis		
Pericarditis	1;	3 0
Pericardial disorders NEC	·`	1
Pericardial rub	,	1 0
Rate and rhythm disorders NEC		
Arrhythmia	į.	1
Bradycardia		0
Cardiac fibrillation		i o
Cardiac flutter	13	
Extrasystoles		7 0
Postural orthostatic tachycardia syndrom		2 0
Tachyarrhythmia		0
Tachycardia	37	
Supraventricular arrhythmias		
Atrial fibrillation		3 0
Atrial flutter		
Atrial factor	10	
Sinus node dysfunction		0
Sinus tachycardia		
Supraventricular tachycardia		
Ventricular arrhythmias and cardiac arrest		<u> </u>

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
Cardiac disorders Cardiac disorders cont'd		
Cardiac arrest	2	0
Pulseless electrical activity	1	0
Ventricular arrhythmia	1	0
Ventricular extrasystoles	2	0
Ventricular fibrillation	1	0
Ventricular tachycardia	12	0
Cardiac disorders SOC TOTAL	344	4

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
Congenital disorders		
Autosomal chromosomal abnormalities		
Trisomy 18	1	0
Sex chromosomal abnormalities		
Klinefelter's syndrome	1	0
Congenital disorders SOC TOTAL	2	. 0

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
Ear disorders		
Ear disorders NEC		
Ear congestion	1	0
Ear discomfort	2	0
Ear pain	54	0
Ear swelling	1	0
Hearing losses		
Deafness	7	0
Deafness bilateral	2	0
Hypoacusis	9	0
Sudden hearing loss	1	0
Hyperacusia		
Hyperacusis	6	0
Inner ear disorders NEC		
Meniere's disease	3	0
Vestibular disorder	1	0
Inner ear signs and symptoms		
Motion sickness	3	0
Tinnitus	140	0
Vertigo	55	0
Vertigo positional	4	0
Ear disorders SOC TOTAL	289	l o

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
Endocrine disorders		
Acute and chronic thyroiditis		
Thyroiditis	2	<u>2</u> 0
Adrenal cortical hyperfunctions		
Cushingoid		J 0
Adrenal cortical hypofunctions		
Addison's disease		J 0
Adrenocortical insufficiency acute		o
Female gonadal function disorders		
Anovulatory cycle		o
Polycystic ovarian syndrome	,	0
Thyroid disorders NEC		
Goitre	,	0
Thyroid pain		<u>2</u> 0
Thyroid hyperfunction disorders		
Hyperthyroidism		<u>2</u>
Thyroid hypofunction disorders		
Hypothyroidism		<u>2</u> 0
Endocrine disorders SOC TOTAL	14	₊l ol

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

	RA Version: MedDRA 27.0	
Reaction Name	Total	<u>Fatal</u>
Eye disorders		
Amblyopic vision impairment		
Amblyopia		1 0
Cataract conditions		
Cataract		1 0
Choroid and vitreous structural change, deposit an	d degeneration	
Vitreous detachment		3 0
Vitreous floaters		e 0
Conjunctival and corneal bleeding and vascular dis	sorders	
Conjunctival haemorrhage		e 0
Eyelid movement disorders		
Blepharospasm		1 0
Eyelid ptosis		ı  o
Glaucomas (excl congenital)		
Angle closure glaucoma		ı o
Iris and uveal tract infections, irritations and inflam	mations	
Uveitis	3	3 0
Lacrimation disorders		
Dry eye	11	ı o
Lacrimation increased		1
Lid, lash and lacrimal infections, irritations and infla		
Erythema of eyelid		1 0
Eyelid cyst		2 0
Eyelid dyst		0
Swelling of eyelid		_
Lid, lash and lacrimal structural disorders		
Lagophthalmos		1 0
Ocular bleeding and vascular disorders NEC		l U
Eye haemorrhage		5 0
Ocular disorders NEC	,	
Eye disorder		2 0
Eye oedema		
•	83	
Eye pain	15	
Eye swelling Periorbital oedema		
Periorbital swelling Retinal disorder	Į.	
		I U
Ocular infections, inflammations and associated m		
Eye discharge		0
Eye irritation		7 0
Eye pruritus	13	
Ocular hyperaemia	13	0
Ocular nerve and muscle disorders		
Eye movement disorder		0
Ocular myasthenia	· · · · · · · · · · · · · · · · · · ·	1 0
Strabismus		1 0
Tolosa-Hunt syndrome		1 0
Ocular sensation disorders		
Asthenopia	13	1
Photophobia	28	3 0
Pupil disorders		
Miosis	•	_
Mydriasis		

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
Eye disorders Eye disorders cont'd		
Retinal bleeding and vascular disorders (excl retinopathy)		
Retinal vascular occlusion	1	0
Retinal vein occlusion	1	0
Retinal structural change, deposit and degeneration		
Macular hole	1	0
Visual disorders NEC		
Diplopia	20	0
Photopsia	8	0
Scintillating scotoma	1	0
Vision blurred	83	0
Visual field disorders		
Visual field defect	1	0
Visual impairment and blindness (excl colour blindness)		
Blindness	13	0
Blindness transient	1	0
Visual acuity reduced	1	0
Visual impairment	36	0
Eve disorders SOC TOTAL	421	0

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Earliest Reaction Date: 07-Feb-2018	MedDRA Version: MedDRA 27.0		
Reaction Name		<u>Total</u>	<u>Fatal</u>
Gastrointestinal disorders			
Abdominal findings abnormal			
Gastrointestinal sounds abnormal		1	0
Abdominal hernias NEC			
Abdominal hernia		1	0
Acute and chronic pancreatitis			
Pancreatitis		1	0
Anal and rectal signs and symptoms			
Anal pruritus		1	0
Colitis (excl infective)			
Colitis		2	0
Colitis ischaemic		1	0
Inflammatory bowel disease		1	0
Dental disorders NEC			
Malpositioned teeth		1	0
Dental pain and sensation disorders			
Toothache		5	0
Dental surface disorders			
Tooth discolouration		1	0
Diaphragmatic hernias			
Hiatus hernia		2	0
Diarrhoea (excl infective)			
Diarrhoea		202	0
Dyspeptic signs and symptoms			
Dyspepsia		23	0
Epigastric discomfort		1	0
Eructation		2	0
Faecal abnormalities NEC			
Abnormal faeces		1	0
Faeces discoloured		1	0
Flatulence, bloating and distension			
Abdominal distension		15	0
Flatulence		6	0
Gastric and oesophageal haemorrhages			
Gastric haemorrhage		1	0
Gastritis (excl infective)			
Gastritis		3	0
Reflux gastritis		1	0
Gastrointestinal and abdominal pains (excl o	ral and throat)		
Abdominal pain		104	0
Abdominal pain lower		4	0
Abdominal pain upper		135	0
Abdominal rigidity		2	0
Gastrointestinal pain		6	0
Oesophageal pain		1	0
Gastrointestinal atonic and hypomotility disor	ders NEC		
Constipation		11	0
Gastrooesophageal reflux disease		9	0
Gastrointestinal disorders NEC			
Food poisoning		1	0
Functional gastrointestinal disorder		1	0
Gastrointestinal disorder		1	0
Gastrointestinal mucosal dystrophies and se	cretion disorders		

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Earliest Reaction Date: 07-Feb-2018	MedDRA Version: MedDRA 27.0	
Reaction Name	Total	Fatal
Gastrointestinal disorders contestinal disorders co	ont'd	
Barrett's oesophagus	1	0
Gastrointestinal signs and symptoms NEC		
Abdominal discomfort	47	0
Dysphagia	8	0
Odynophagia	1	0
Gastrointestinal spastic and hypermotility dis	sorders	
Cardiospasm	10	0
Irritable bowel syndrome	4	0
Gastrointestinal vascular malformations		
Gastric antral vascular ectasia	1	0
Gastrointestinal vascular occlusion and infai	rction	
Intestinal infarction	1	0
Intestinal ischaemia	1	0
Mesenteric vein thrombosis	1	0
Gingival disorders, signs and symptoms NE	C	
Gingival blister	3	0
Gingival pain	6	
Noninfective gingivitis	1	o o
Gingival haemorrhages		
Gingival bleeding	4	0
Haemorrhoids and gastrointestinal varices (		
Haemorrhoids	2	0
Haemorrhoids thrombosed	1	0
Intestinal haemorrhages	'	٠
	2	_
Anal haemorrhage	2 3	0
Rectal haemorrhage	3	
Small intestinal haemorrhage	1	0
Malabsorption syndromes		
Coeliac disease	2	0
Nausea and vomiting symptoms	750	
Nausea	752	
Regurgitation	1	0
Retching	8	0
Vomiting	230	
Vomiting projectile	2	0
Non-site specific gastrointestinal haemorrha	ges	_
Gastrointestinal haemorrhage	1	0
Haematemesis	2	I
Haematochezia	4	0
Oesophagitis (excl infective)		
Oesophagitis	2	0
Oral dryness and saliva altered		
Dry mouth	36	
Lip dry	6	0
Salivary hypersecretion	1	0
Oral soft tissue disorders NEC		
Chapped lips	1	0
Oral disorder	1	0
Oral soft tissue haemorrhages		
Mouth haemorrhage	2	0
Oral blood blister	1	I
Oral soft tissue infections		

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
Gastrointestinal disorders ointestinal disorders cont'd	Total	i atai
Angular cheilitis	1	0
Oral soft tissue signs and symptoms		J
Burning mouth syndrome	1	0
Hypoaesthesia oral	19	0
Oral discomfort	4	0
Oral pain	5	0
Oral pruritus	1	0
Paraesthesia oral	26	0
Oral soft tissue swelling and oedema		
Lip swelling	37	0
Mouth swelling	3	0
Palatal swelling	2	0
Peritoneal and retroperitoneal disorders		
Ascites	1	0
Salivary gland enlargements		
Parotid gland enlargement	1	0
Stomatitis and ulceration		
Aphthous ulcer	5	0
Lip ulceration	1	0
Mouth ulceration	19	0
Stomatitis	2	0
Tongue disorders		
Trichoglossia	1	0
Tongue signs and symptoms		
Glossodynia	6	0
Swollen tongue	22	0
Tongue discolouration	2	0
Tongue discomfort	1	0
Tongue dry	2	0
Tongue oedema	1	0
Tongue rough	1	0
Tongue spasm	1	0
Gastrointestinal disorders SOC TOTAL	1863	0

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Earliest Reaction Date: 07-Feb-2018	MedDRA Version: MedDRA 27.0		
Reaction Name		<u>Total</u>	<u>Fatal</u>
General disorders General disorders cont'd			
Multiple organ dysfunction syndrome		1	0
Peripheral swelling		178	0
Pre-existing condition improved		1	0
Secretion discharge		1	0
Swelling		61	0
Swelling face		27	0
Implant and catheter site reactions			
Implant site swelling		1	0
Implant site warmth		1	0
Inflammations			
Inflammation		24	0
Scar inflammation		1	0
Infusion site reactions			
Infusion site pain		2	0
Infusion site warmth		1	0
Injection site reactions			Ŭ
Injected limb mobility decreased		3	0
Injection site bruising		3	0
Injection site coldness		ا 1	0
Injection site codificas		22	0
Injection site erytherna Injection site inflammation			0
Injection site joint pain		3 2	0
Injection site mass		39	0
Injection site mass Injection site oedema		1	0
Injection site bedema		120	
			0
Injection site paraesthesia		1 7	
Injection site pruritus		12	0
Injection site rash		I I	
Injection site reaction		1	0
Injection site swelling		6 1	
Injection site urticaria			0
Injection site vesicles		2 12	
Injection site warmth		12	0
Instillation site reactions		ارا	^
Instillation site pain		1	0
Instillation site warmth		2	0
Interactions		_	•
Drug interaction		1	0
Inhibitory drug interaction		1	0
Mass conditions NEC			_
Cyst		2	0
Mass		1	0
Nodule		1	0
Mucosal findings abnormal			
Oedema mucosal		1	0
Necrosis NEC			
Necrosis		1	0
Oedema NEC			
Localised oedema		1	0
Oedema		6	0
Oedema peripheral		5	0
Pain and discomfort NEC			

### Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
General disorders General disorders cont'd		
Axillary pain	19	0
Chest discomfort	39	0
Chest pain	144	0
Discomfort	21	0
Facial pain	19	0
Inflammatory pain	1	0
Pain	460	0
Tenderness	47	0
Therapeutic and nontherapeutic responses		
Adverse drug reaction	4	0
Adverse food reaction	1	0
Drug ineffective	9	0
Therapeutic response unexpected	4	0
Vaccination failure	1	0
Ulcers NEC		
Ulcer	1	0
Vaccination site reactions		
Shoulder injury related to vaccine administration	3	0
Vaccination site bruising	3	0
Vaccination site discolouration	1	0
Vaccination site erythema	19	0
Vaccination site hypoaesthesia	1	0
Vaccination site joint pain	3	0
Vaccination site mass	16	0
Vaccination site movement impairment	4	0
Vaccination site pain	64	0
Vaccination site pruritus	4	0
Vaccination site rash	4	0
Vaccination site scar	1	0
Vaccination site swelling	9	0
Vaccination site warmth	11	0
Withdrawal and rebound effects		
Withdrawal syndrome	1	0
General disorders SOC TOTAL	5786	4

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
Hepatic disorders		
Cholecystitis and cholelithiasis		
Cholelithiasis	1	0
Cholestasis and jaundice		
Cholestasis	1	0
Jaundice		0
Gallbladder disorders NEC		
Gallbladder disorder		0
Hepatic fibrosis and cirrhosis		
Hepatic cirrhosis		0
Hepatic vascular disorders		
Hepatic vein thrombosis	1	0
Hepatobiliary signs and symptoms		
Hepatic pain	5	0
Liver tenderness	1	0
Hepatocellular damage and hepatitis NEC		
Hepatic necrosis	1	0
Hepatitis	1	0
Hepatitis acute	1	0
Hepatic disorders SOC TOTAL	15	il ol

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
Immune system disorders		
Acute and chronic sarcoidosis		
Sarcoidosis	1	0
Allergic conditions NEC		
Allergic oedema	1	0
Hypersensitivity	48	0
Allergies to foods, food additives, drugs and other chemicals		
Allergy to vaccine	1	0
Drug hypersensitivity	2	0
Food allergy	2	0
Reaction to excipient	1	0
Reaction to preservatives	2	0
Anaphylactic and anaphylactoid responses		
Anaphylactic reaction	17	0
Anaphylactic shock	3	0
Atopic disorders		
Seasonal allergy	4	0
Autoimmune disorders NEC		
Autoimmune disorder	4	0
Immune and associated conditions NEC		
Immune system disorder	3	0
Immune system disorders SOC TOTAL	89	l ol

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Earliest Reaction Date: 07-Feb-2018	MedDRA Version: MedDRA 27.0		
Reaction Name		<u>Total</u>	<u>Fatal</u>
Infections			
Abdominal and gastrointestinal infections			
Appendicitis perforated		1	0
Diverticulitis		1	0
Bacterial infections NEC			
Bacterial infection		3	0
Cellulitis		12	0
Pneumonia bacterial		1	0
Skin bacterial infection		1	0
Bone and joint infections			
Bursitis infective		1	0
Borrelial infections			
Lyme disease		1	0
Campylobacter infections			
Campylobacter gastroenteritis		1	0
Candida infections			
Candida infection		4	0
Oral candidiasis		2 1	0
Vulvovaginal candidiasis		1	0
Central nervous system and spinal infection	s		
Cavernous sinus thrombosis		1	0
Encephalitis		1	0
Encephalomyelitis		1	0
Meningitis		2	0
Coronavirus infections			
COVID-19		68	0
Suspected COVID-19		1	0
Coxiella infections			
Q fever		2	0
Dental and oral soft tissue infections			
Gingivitis		2	0
Parotitis		1	0
Ear infections			
Ear infection		2	0
Labyrinthitis		2 9	0
Epstein-Barr viral infections			
Infectious mononucleosis		1	0
Eye and eyelid infections			
Conjunctivitis		4	0
Eye infection		2 1	0
Retinitis		1	0
Female reproductive tract infections			
Ovarian abscess		1	0
Fungal infections NEC			
Fungal infection		1	0
Herpes viral infections			
Genital herpes		1	0
Herpes simplex		1	0
Herpes virus infection		2	0
Herpes zoster		30	
Herpes zoster oticus		2	0
Ophthalmic herpes zoster		1	
Oral herpes		11	0

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Earliest Reaction Date: 07-Feb-2018	MedDRA Version: MedDRA 27.0		
Reaction Name		<u>Total</u>	<u>Fatal</u>
Infections Infections cont'd			
Varicella		3	0
Infections NEC			
Abscess		2 1	0
Infected bite		1	0
Infection		20	0
Injection site infection		2	0
Localised infection		3	0
Toxic shock syndrome		1	0
Influenza viral infections			
H1N1 influenza		1	0
Influenza		157	0
Lower respiratory tract and lung infections			
Bronchitis		1	0
Lower respiratory tract infection		6	0
Pneumonia		8	0
Plasmodia infections			
Malaria		1	0
Retroviral infections			
HIV infection		1	0
Salmonella infections			
Typhoid fever		1	0
Sepsis, bacteraemia, viraemia and fungaemi	a NEC		
Sepsis		7	1
Skin structures and soft tissue infections			
Impetigo		1	0
Pustule		1	0
Rash pustular		1	0
Skin infection		3	0
Streptococcal infections			
Pharyngitis streptococcal		1	0
Tinea infections			
Tinea pedis		1	0
Tuberculous infections			
Pulmonary tuberculosis		1	0
Tuberculosis		2	0
Upper respiratory tract infections			
Laryngitis		3	0
Nasopharyngitis		55	0
Rhinitis		1	0
Sinusitis		5	0
Tonsillitis		3	0
Urinary tract infections			
Cystitis		3	0
Urinary tract infection		3 7	0
Viral infections NEC			
Encephalitis viral		1	0
Gastroenteritis viral		3	0
Meningitis viral		1	0
Sweating fever		13	
Vestibular neuronitis		3	0
Viral infection		3	
Viral rash		1	0

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Na	ame	Total	Fatal
Infections	Infections cont'd		
Infections SO	C TOTAL	505	5 1

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Earliest Reaction Date: 07-Feb-2018	MedDRA Version: MedDRA 27.0		
Reaction Name		<u>Total</u>	<u>Fatal</u>
Injuries			
Cardiac and vascular procedural complication	ns		
Vascular access site bruising		1	0
Cerebral injuries NEC			
Brain herniation		1	0
Extradural haematoma		1	0
Subdural haemorrhage		1	0
Chest and respiratory tract injuries NEC			
Chest crushing		1	0
Conditions caused by cold			
Chillblains		4	0
Exposures associated with pregnancy, delive	ery and lactation		
Exposure via breast milk		3	0
Foetal exposure during pregnancy		1	0
Maternal exposure during breast feeding		28	0
Maternal exposure during pregnancy		6	0
Eye injuries NEC			
Eye contusion		3	0
Eye injury		1	0
Foreign body in eye		1	0
Fractures and dislocations NEC			_
Joint dislocation		1	0
Intentional product misuses			_
Intentional product misuse		11	0
Intentional product use issues			Ŭ
Intentional product use issue		8	0
Limb fractures and dislocations		Ĭ	Ŭ
Clavicle fracture		1	0
Femur fracture		1	0
Medication errors, product use errors and iss	sues NEC	·	J
Wrong technique in product usage process		1	0
Muscle, tendon and ligament injuries		·	
Ligament injury		1	0
Ligament rupture		1	0
Ligament sprain		1	0
Muscle injury		_	0
Tendon injury		2 2	0
Tendon rupture		2	0
Nerve injuries NEC			Ŭ
Nerve injury		6	0
Neurological and psychiatric procedural com	plications	Ĭ	Ŭ
Procedural dizziness	p.1104.110	2	0
Non-site specific injuries NEC		_	ŭ
Animal bite		1	0
Electric shock		1	0
Fall		6	0
Inflammation of wound		1	0
Injury		1	0
Wound complication		1	0
Non-site specific procedural complications		1	U
Infusion related reaction			0
		1	0
Injection related reaction		6	0
Post procedural complication		1	0

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
Injuries cont'd	10101	
Post procedural contusion	1	0
Off label uses		
Off label use		0
Overdoses NEC		
Intentional overdose	1	0
Pathways and sources of exposure		
Exposure via body fluid	1	0
Product administration errors and issues		
Contraindicated product administered	1	0
Expired product administered	2	2 0
Inappropriate schedule of product administration	4	0
Incomplete course of vaccination	1	0
Incorrect dose administered	1	0
Incorrect route of product administration	1	0
Product administered to patient of inappropriate age	) 2	2 0
Product administration error	1	0
Product dose omission issue	1	0
Product dispensing errors and issues		
Product dispensing error	1	0
Product prescribing errors and issues		
Product prescribing error	1	0
Radiation injuries		
Sunburn	1	0
Site specific injuries NEC		
Head injury	1	0
Limb injury	7	0
Skin injuries NEC		
Contusion	105	0
Scar		0
Thermal burns		
Thermal burns of eye	1	0
Vaccination related complications		
Immunisation reaction	3	0
Injuries SOC TOTAL	260	0

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Earliest Reaction Date: 07-Feb-2018	MedDRA Version: MedDRA 27.0		
Reaction Name	Tota	<u>ıL</u> ,	<u>Fatal</u>
Investigations			
Auditory and vestibular diagnostic procedures	3		
Acoustic stimulation tests		1	0
Blood gas and acid base analyses			
Blood pH increased		1	0
Carbon dioxide increased		1	0
Oxygen saturation decreased		3	0
Carbohydrate tolerance analyses (incl diabet	es)		
Blood glucose		1	0
Blood glucose fluctuation		2	0
Blood glucose increased		11	0
Cardiac auscultatory investigations			
Cardiac murmur		1	0
Heart sounds		1	0
Central nervous system imaging procedures			
Computerised tomogram head		2	0
Cerebrospinal fluid tests (excl microbiology)			
CSF pressure		2	0
Coagulation and bleeding analyses			_
Activated partial thromboplastin time prolon	aed	2	0
Coagulation factor VIII level decreased	9	1	0
Coagulation time		1	0
Fibrin D dimer		1	0
International normalised ratio increased		1	0
ECG investigations			J
Electrocardiogram		1	0
Endocrine analyses and imaging NEC		- 1	J
Hormone level abnormal		4	0
Faecal analyses NEC			J
Faecal calprotectin increased		4	0
Heart rate and pulse investigations		- 1	J
Heart rate and pulse investigations		26	0
Heart rate abnormal		20	0
Heart rate abnormal  Heart rate decreased		5	0
Heart rate decreased  Heart rate increased		49	0
		49	0
Heart rate irregular  Maximum heart rate		1	0
Pulse abnormal		4	
		- 1	0
Hepatobiliary function diagnostic procedures Liver function test abnormal		4	0
Transaminases increased		1	0
		1	U
Immunoglobulin analyses			0
Blood immunoglobulin E		1	0
Immunology skin tests NEC			0
Allergy alert test		1	0
Skin test positive		1	0
Investigations NEC			_
Blood test		3	0
Blood test abnormal		1	0
Laboratory test		1	0
Metabolism tests NEC			
Blood ketone body		1	0
N-terminal prohormone brain natriuretic per	otide increased	1	0

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0		
Reaction Name	<u>Total</u>	Fatal
Investigations Investigations cont'd		
Mineral and electrolyte analyses		
Blood calcium decreased	1	0
Blood iron decreased	2	0
Blood iron increased	1	0
Blood phosphorus decreased	1	0
Blood potassium decreased	1	0
Blood sodium decreased	1	0
Serum ferritin	1	0
Musculoskeletal and soft tissue imaging procedures		
Skull X-ray	2	0
X-ray limb abnormal	1	0
Musculoskeletal and soft tissue tests NEC		
Muscle mass percentage	1	0
Tender joint count	1	0
Neurologic diagnostic procedures		
Coma scale abnormal	1	0
Lumbar puncture	2	0
Ophthalmic function diagnostic procedures		
Visual tracking test	1	0
Physical examination procedures and organ system status		
Body temperature	17	0
Body temperature abnormal	2	0
Body temperature decreased	1	0
Body temperature fluctuation	5	0
Body temperature increased	37	0
Grip strength	2	0
Grip strength decreased	2	0
Menstruation normal	1	0
Respiratory rate decreased	2	0
Respiratory rate increased	4	
Skin temperature	3	0
Weight decreased	6	
Weight increased	2	Ö
Pituitary analyses anterior		
Blood thyroid stimulating hormone decreased	1	0
Blood thyroid stimulating hormone increased	1	0
Platelet analyses		Ŭ
Platelet count decreased	7	0
Platelet count increased	1	0
Protein analyses NEC	'	
C-reactive protein increased	3	0
Red blood cell analyses	٦	J
Haemoglobin	1	0
Haemoglobin decreased	1	0
Respiratory and pulmonary function diagnostic procedures	'	U
	1	0
Pulmonary function test decreased	1	0
Slow vital capacity	1	
Total lung capacity decreased	1	0
Urinalysis NEC	4	
Blood urine	1	0
Blood urine present	1	0
Glucose urine	1	0

### Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
Investigations Investigations cont'd		
Vascular tests NEC (incl blood pressure)		
Blood pressure decreased	1	0
Blood pressure increased	7	0
Blood pressure measurement	1	0
Virus identification and serology		
SARS-CoV-2 antibody test	1	0
SARS-CoV-2 test positive	1	0
Viral test	1	0
Vitamin analyses		
Vitamin B12 increased	1	0
White blood cell analyses		
Eosinophil count increased	1	0
Neutrophil count decreased	1	0
White blood cell count	1	0
White blood cell count decreased	1	0
Investigations SOC TOTAL	279	0

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0		
Reaction Name	<u>  Total                                    </u>	<u>Fatal</u>
Metabolic disorders		
Appetite disorders		
Appetite disorder	5	0
Decreased appetite	115	0
Food craving	1	0
Hypophagia	1	0
Increased appetite	3	0
Diabetes mellitus (incl subtypes)		
Diabetes mellitus inadequate control	2	0
Diabetic complications NEC		
Diabetic ketoacidosis	1	0
Disorders of purine metabolism		
Gout	3	0
Fat soluble vitamin deficiencies and disorders		
Vitamin D deficiency	1	0
Fluid intake increased		
Polydipsia	2	0
Food malabsorption and intolerance syndromes (excl sugar intolerance)		
Histamine intolerance	2	0
General nutritional disorders NEC		
Abnormal loss of weight	1	0
Abnormal weight gain	2	0
Feeding disorder	5	0
Food aversion	1	0
Hyperglycaemic conditions NEC		
Hyperglycaemia	1	0
Hypoglycaemic conditions NEC		
Hypoglycaemia	1	0
Iron deficiencies		
Iron deficiency	1	0
Potassium imbalance		
Hypokalaemic syndrome	2	0
Total fluid volume decreased		
Dehydration	29	0
Total fluid volume increased		
Fluid retention	1	О
Vitamin deficiencies NEC	·	J
Hypovitaminosis	1	0
Metabolic disorders SOC TOTAL	181	Ö

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

	MedDRA Version: MedDRA 27.0		
Reaction Name		<u>Total</u>	<u>Fatal</u>
Muscle & tissue disorders			
Arthropathies NEC			
Arthritis		14	0
Arthropathy		1	0
Autoimmune arthritis		1	0
Haemarthrosis		1	0
Polyarthritis		1	0
Rheumatic fever		1	0
Bone disorders NEC			
Medial tibial stress syndrome		1	0
Bone related signs and symptoms			
Bone pain		18	0
Bone swelling		1	0
Coccydynia		1	0
Pain in jaw		20	0
Spinal pain		4	0
Bursal disorders		·	Ŭ
Bursitis		6	0
Cartilage disorders		Ŭ	Ŭ
Costochondritis		3	0
Connective tissue disorders NEC		J	J
Connective tissue disorder		2	0
Eosinophilic fasciitis		2 1	0
Polymyalgia rheumatica		1	0
Sjogren's syndrome		, 1	0
Joint related disorders NEC			U
		1	0
Ligament laxity Periarthritis		21	0
		Z I	0
Rotator cuff syndrome		ı	U
Joint related signs and symptoms		EEO	0
Arthralgia		559	0
Joint stiffness		9	0
Joint swelling		16	
Joint vibration		1	0
Metabolic bone disorders		_	0
Osteoporosis		2	0
Muscle pains		4.0	•
Fibromyalgia		10	0
Myalgia		585	0
Myofascial pain syndrome		1	0
Muscle related signs and symptoms NEC			_
Muscle discomfort		1	0
Muscle fatigue		29	0
Muscle spasms		86	0
Muscle swelling		1	
Muscle tightness		7	0
Muscle twitching		33	0
Muscle tone abnormalities			
Muscle rigidity		1	0
Muscle weakness conditions			
Muscular weakness		54	0
Musculoskeletal and connective tissue conditi	ons NEC		
Limb mass		2	0

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
Muscle & tissue disorders & tissue disorders cont'd		
Mobility decreased	4	0
Musculoskeletal stiffness	70	0
Musculoskeletal and connective tissue deformities of skull, face and buccal cavity		
Facial asymmetry	1	0
Head deformity	1	0
Musculoskeletal and connective tissue pain and discomfort		
Back pain	114	0
Limb discomfort	71	0
Musculoskeletal chest pain	3	0
Musculoskeletal discomfort	4	0
Musculoskeletal pain	5	0
Neck pain	75	0
Pain in extremity	585	0
Rheumatic disorder	1	0
Osteoarthropathies		
Osteoarthritis	3	0
Spinal osteoarthritis	1	0
Rheumatoid arthropathies		
Rheumatoid arthritis	5	0
Soft tissue disorders NEC		
Axillary mass	2	0
Groin pain	5	0
Neck mass	2	0
Spondyloarthropathies		
Ankylosing spondylitis	1	0
Spondylitis	1	0
Tendon disorders		
Tendon discomfort	1	0
Tendon pain	2	0
Tendonitis	5	0
Muscle & tissue disorders SOC TOTAL	2460	0

### Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
Neoplasms		
Breast and nipple neoplasms malignant		
Breast cancer	1	0
Breast cancer stage III	1	0
Cardiovascular neoplasms benign		
Haemangioma	1	0
Neoplasms malignant site unspecified NEC		
Adenocarcinoma	1	0
Neoplasm malignant	1	0
Nervous system neoplasms unspecified malignancy NEC		
Schwannoma	1	0
Oesophageal neoplasms malignant		
Oesophageal cancer metastatic	1	0
Ovarian neoplasms malignant (excl germ cell)		
Ovarian cancer	1	0
Respiratory tract and pleural neoplasms malignant cell type unspecified NEC		
Bronchial carcinoma	1	0
Lung neoplasm malignant	1	0
Skin neoplasms benign		
Skin papilloma	1	0
Neoplasms SOC TOTAL	11	0

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Earliest Reaction Date: 07-Feb-2018	MedDRA Version: MedDRA 27.0		
Reaction Name		<u>Total</u>	<u>Fatal</u>
Nervous system disorders			
Absence seizures			
Petit mal epilepsy		1	0
Acute polyneuropathies			
Guillain-Barre syndrome		9	0
Central nervous system haemorrhages and	cerebrovascular accidents		
Basal ganglia haemorrhage		1	0
Carotid artery occlusion		10	0
Cerebral haemorrhage		5	0
Cerebral infarction		1	0
Cerebrovascular accident		35	0
Haemorrhage intracranial		2	0
Ischaemic stroke		2	0
Subarachnoid haemorrhage		14	0
Cerebrovascular venous and sinus thrombo	osis		
Cerebral venous sinus thrombosis		2	1
Cerebral venous thrombosis		1	0
Chronic polyneuropathies			
Chronic inflammatory demyelinating polyr	adiculoneuropathy	1	0
Demyelinating polyneuropathy		1	0
Coma states			
Coma		2	0
Coordination and balance disturbances			
Balance disorder		25	0
Coordination abnormal		7	0
Dysstasia		4	0
Hand-eye coordination impaired		1	0
Cortical dysfunction NEC			
Aphasia		5	0
Dysgraphia		1	0
Demyelinating disorders NEC			
Acute disseminated encephalomyelitis		1	0
Disturbances in consciousness NEC			
Depressed level of consciousness		3	0
Lethargy		105	0
Loss of consciousness		29	0
Somnolence		42	0
Syncope		63	0
Disturbances in sleep phase rhythm			_
Irregular sleep phase		1	0
Dyskinesias and movement disorders NEC		_	_
Bradykinesia		1	0
Clumsiness		2	0
Dyskinesia		2	0
Hyperkinesia			0
Hypokinesia		3	0
Movement disorder		5	0
Facial cranial nerve disorders			
Bell's palsy		13	0
Facial paralysis		8	0
Facial paresis		8	0
Facial spasm		3	0
Generalised tonic-clonic seizures			

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Earliest Reaction Date: 07-Feb-2018	MedDRA Version: MedDRA 27.0		
Reaction Name		<u>Total</u>	<u>Fatal</u>
Nervous system disorders us system disorders	cont'd		
Generalised tonic-clonic seizure		7	0
Headaches NEC			
Cluster headache		19	0
Cold-stimulus headache		1	0
Headache		1913	0
Medication overuse headache		1	0
Menstrual headache		1	0
New daily persistent headache		1	0
Occipital neuralgia		2	0
Primary stabbing headache		5	0
Sinus headache		24	0
Tension headache		43	0
Thunderclap headache		2	0
Vascular headache		4	0
Increased intracranial pressure disorders			
Brain oedema		1	0
Intracranial pressure increased		1	0
Lumbar spinal cord and nerve root disorder	s		
Sciatica		7	0
Memory loss (excl dementia)			
Amnesia		20	0
Memory impairment		20	0
Mental impairment (excl dementia and men	nory loss)		
Cognitive disorder	·	13	0
Disturbance in attention		24	0
Judgement impaired		1	0
Mental impairment		1	0
Migraine headaches			
Hemiplegic migraine		2	0
Migraine		197	0
Migraine with aura		11	0
Migraine without aura		1	0
Retinal migraine		2	0
Typical aura without headache		1	0
Vestibular migraine		2	0
Mononeuropathies			
Carpal tunnel syndrome		3	0
Nerve compression		1	0
Peroneal nerve palsy		2	0
Motor neurone diseases			
Lower motor neurone lesion		1	0
Multiple sclerosis acute and progressive			
Multiple sclerosis		1	0
Multiple sclerosis relapse		1	0
Myelitis (incl infective)			
Myelitis transverse		2	0
Narcolepsy and hypersomnia			
Hypersomnia		5	0
Nervous system disorders NEC			
Brain stem syndrome		1	0
Central nervous system lesion		1	0
Nervous system disorder		2	0

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Earliest Reaction Date: 07-Feb-2018	MedDRA Version: MedDRA 27.0		
Reaction Name		<u>Total</u>	<u>Fatal</u>
Nervous system disorders co	ont'd		
Neurological signs and symptoms NEC			
Brain fog		31	0
Dizziness		584	0
Dizziness postural		49	0
Drooling		2	0
Head discomfort		20	0
Myoclonus		2	0
Neurological symptom		3	0
Presyncope		22	0
Tongue biting		1	0
Unresponsive to stimuli		2	0
Neuromuscular disorders NEC			J
Muscle contractions involuntary		2	0
Muscle spasticity		2 1	0
Neuromuscular junction dysfunction			U
Myasthenia gravis		1	0
Olfactory nerve disorders			U
Anosmia		19	0
Parosmia		18	0
Paraesthesias and dysaesthesias		10	U
		31	0
Burning sensation Formication			0
		6	
Hemiparaesthesia		1	0
Hyperaesthesia		100	
Hypoaesthesia		180	0
Paraesthesia		287	U
Paralysis and paresis (excl cranial nerve)		0	0
Hemiparesis		2	0
Hemiplegia		1	0
Monoparesis		3	0
Monoplegia		3	0
Paralysis NEO		10	0
Partial simple seizures NEC		0	0
Simple partial seizures		2	0
Peripheral neuropathies NEC			•
Neuropathy peripheral		4	0
Peripheral sensory neuropathy		7	0
Seizures and seizure disorders NEC		40	0
Epilepsy		13	0
Febrile convulsion		1	0
Myoclonic epilepsy		1	0
Partial seizures		1	0
Seizure		31	0
Seizure like phenomena		1	0
Tonic convulsion		1	0
Sensory abnormalities NEC			_
Ageusia		20	0
Dysgeusia		66	0
Electric shock sensation		5	0
Hypogeusia		1	0
Neuralgia		24	0
Restless arm syndrome		1	0

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
Nervous system disorders us system disorders cont'd		
Restless legs syndrome	10	0
Sensory disturbance	5	0
Sensory loss	7	0
Taste disorder	9	0
Sleep disturbances NEC		
Sleep deficit	2	0
Speech and language abnormalities		
Dysarthria	8	0
Incoherent	1	0
Repetitive speech	1	0
Slow speech	2	0
Speech disorder	4	0
Spinal cord and nerve root disorders NEC		
Radiculitis brachial	1	0
Subacute combined cord degeneration	1	0
Structural brain disorders NEC		
Brain injury	2	0
Cerebral mass effect	1	0
Transient cerebrovascular events		
Transient ischaemic attack	14	0
Tremor (excl congenital)		
Head titubation	1	0
Tremor	165	0
Trigeminal disorders		
Trigeminal neuralgia	5	0
Vagus nerve disorders		
Vocal cord paralysis	1	0
Nervous system disorders SOC TOTAL	4464	1

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
Pregnancy conditions		
Abortions spontaneous		
Abortion spontaneous	4	0
Pregnancy conditions SOC TOTAL	4	0

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
Device malfunction events NEC		
Oversensing	1	0
Product physical issues		
Product after taste	1	0
null SOC TOTAL	2	0

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Earliest Reaction Date: 07-Feb-2018	MedDRA Version: MedDRA 27.0		
Reaction Name		<u>otal</u>	<u>Fatal</u>
Psychiatric disorders			
Abnormal behaviour NEC			
Abnormal behaviour		1	0
Affect alterations NEC			
Constricted affect		1	0
Flat affect		1	0
Amnestic symptoms		•	,
Paramnesia		1	0
Anxiety symptoms		'	
Agitation		1	0
Anxiety		32	
Nervousness		10	
Stress		4	
Tension		2	0
			0
Behaviour and socialisation disturbances		4	_
Paranoia	NEO	1	0
Cognitive and attention disorders and disturb	ances NEC	4-7	_
Mental fatigue		17	0
Confusion and disorientation			_
Confusional state		44	
Disorientation		17	0
Deliria			
Delirium		11	0
Delusional symptoms			
Delusion		2	0
Depressive disorders			
Depression		20	0
Depression suicidal		1	0
Dissociative states			
Dissociation		4	0
Disturbances in initiating and maintaining sle	ep		
Insomnia		79	0
Middle insomnia		2	0
Dyssomnias			
Poor quality sleep		21	0
Eating disorders NEC			
Eating disorder		2	0
Emotional and mood disturbances NEC			
Anger		2	0
Emotional disorder		2	0
Emotional distress		2 5	0
Euphoric mood		4	0
Irritability		8	0
Mood altered		3	0
Fluctuating mood symptoms		Ĭ	_
Mood swings		8	0
Hallucinations (excl sleep-related)		J	
Hallucination		23	0
Hallucination, olfactory		1	0
Hallucination, visual		1	0
Increased physical activity levels		1	"
Restlessness		4.0	^
		16	0
Mood alterations with depressive symptoms			

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0		
Reaction Name	<u> Total</u>	<u>Fatal</u>
Psychiatric disorders <sup>Psychiatric</sup> disorders cont'd		
Decreased interest	1	0
Depressed mood	16	0
Tearfulness	3	0
Mood disorders NEC		
Listless	2	0
Obsessive-compulsive disorders and symptoms		
Body dysmorphic disorder	1	0
Compulsive shopping	1	0
Orgasmic disorders and disturbances		
Orgasmic sensation decreased	1	0
Panic attacks and disorders		
Panic attack	6	0
Panic reaction	2	0
Parasomnias		
Abnormal dreams	5	0
Nightmare	14	0
Sleep terror	9	0
Sleep-related eating disorder	1	0
Somnambulism	1	0
Perception disturbances NEC	•	
Autoscopy	1	0
Derealisation	1	0
Psychiatric elimination disorders		U
Enuresis	2	0
Psychiatric symptoms NEC		U
Hypervigilance	1	0
Psychological trauma	1	0
	I	U
Psychotic disorder NEC	4	^
Psychotic disorder	1	0
Sexual arousal disorders		^
Disturbance in sexual arousal	2	0
Sexual desire disorders		^
Libido decreased	1	0
Sleep disorders NEC	4.0	
Sleep disorder	12	0
Somatic symptom disorders		
Conversion disorder	1	0
Habit cough	1	0
Speech and language usage disturbances		_
Disorganised speech	1	0
Stereotypies and automatisms		
Head banging	1	0
Substance related and addictive disorders		
Drug abuse	1	0
Suicidal and self-injurious behaviour		
Suicidal ideation	2	0
Suicide attempt	1	0
Thinking disturbances		
Bradyphrenia	2	0
Impaired reasoning	1	0
Tachyphrenia	1	0
Thinking abnormal	1	0

## Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
Psychiatric disorders Psychiatric disorders cont'd		
Thought blocking	1	0
Tic disorders		
Tic	1	0
Psychiatric disorders SOC TOTAL	450	0

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	 otal	Fatal
Renal & urinary disorders		
Bladder and urethral symptoms		
Bladder pain	3	0
Dysuria	3	0
Incontinence	2	0
Micturition urgency	2	0
Pollakiuria	9	0
Urethral pain	1	0
Urinary incontinence	1	0
Urinary retention	3	0
Urine flow decreased	1	0
Bladder infections and inflammations		
Cystitis interstitial	1	0
Genital and urinary tract disorders NEC		
Urinary tract disorder	1	0
Myoneurogenic bladder disorders		
Bladder dysfunction	1	0
Hypertonic bladder	1	0
Renal disorders NEC		
Renal disorder	1	0
Renal failure and impairment		
Acute kidney injury	1	0
Anuria	1	0
Oliguria	1	0
Renal lithiasis		
Nephrolithiasis	1	0
Urinary abnormalities		
Urine odour abnormal	1	0
Urinary tract signs and symptoms NEC		
Polyuria	1	0
Renal pain	17	0
Urinary tract pain	1	0
Renal & urinary disorders SOC TOTAL	54	0

## Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Earliest Reaction Date: 07-Feb-2018	MedDRA Version: MedDRA 27.0	
Reaction Name	Total	Fatal
Reproductive & breast disorders		
Breast signs and symptoms		
Breast pain	13	3 0
Breast swelling		2 0
Breast tenderness		3l ol
Cervix neoplasms		
Cervical polyp		1 0
Erection and ejaculation conditions and disc		1
Erectile dysfunction		3 0
Menopausal effects NEC		1 1
Menopausal disorder		1 0
Menopausal symptoms		3 0
Premature menopause		1 0
Menopausal effects on the genitourinary trace	~+	1
Postmenopausal haemorrhage		3 0
Menstruation and uterine bleeding NEC		1
Dysmenorrhoea	18	3 0
Intermenstrual bleeding	17	
Menstrual disorder	32	
	46	
Menstruation irregular		
Premenstrual syndrome Withdrawal bleed		
		1 0
Menstruation with decreased bleeding	4,	
Amenorrhoea	12	
Hypomenorrhoea	12	
Menstruation delayed	47	
Oligomenorrhoea	,	3 0
Menstruation with increased bleeding		
Heavy menstrual bleeding	75	1
Polymenorrhoea		9 0
Ovarian and fallopian tube cysts and neopla		
Ovarian cyst		3 0
Pelvis and broad ligament disorders NEC		
_Adnexa uteri pain	2	2 0
Prostatic neoplasms and hypertrophy		
Benign prostatic hyperplasia		1 0
Prostatic signs, symptoms and disorders NE		
Prostatomegaly		1 0
Reproductive tract disorders NEC (excl neo	olasms)	
Genital haemorrhage	·	1 0
Genital lesion		1 0
Reproductive tract signs and symptoms NE		
Pelvic pain		1 0
Pruritus genital	10	0
Scrotal disorders NEC		
Scrotal pain		1 0
Sexual function and fertility disorders NEC		
Infertility	•	1 0
Uterine disorders NEC		
Endometriosis		1 0
Uterine haemorrhage		3 0
Uterine pain		1 0
Vulvovaginal disorders NEC		

## Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
Reproductive & breast disorders cont'd		
Vaginal haemorrhage	28	0
Vulval haemorrhage	1	0
Vulvovaginal signs and symptoms		
Vaginal discharge	3	0
Vulvovaginal burning sensation	1	0
Vulvovaginal dryness	1	0
Vulvovaginal pain	1	0
Vulvovaginal pruritus	1	0
Reproductive & breast disorders SOC TOTAL	377	0

## Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Earliest Reaction Date: 07-Feb-2018	MedDRA Version: MedDRA 27.0		
Reaction Name		<u>Total</u>	Fatal
Respiratory disorders			
Breathing abnormalities			
Dyspnoea		201	0
Dyspnoea at rest		1	0
Dyspnoea exertional		2	0
Hyperventilation		3	0
Hypopnoea		3 2	0
Irregular breathing		1	0
Respiration abnormal		4	0
Bronchospasm and obstruction			
Asthma		12	0
Asthma exercise induced		1	0
Chronic obstructive pulmonary disease		1	0
Wheezing		16	0
Conditions associated with abnormal gas exc	change		Ŭ
Hypercapnia	mango	1	0
Hypoxia		3	0
Coughing and associated symptoms		ĭ	U
Allergic cough		1	0
Cough		96	0
Haemoptysis		4	0
Productive cough		3	0
Sputum discoloured		1	0
	nunciagia conditiona	I	U
Lower respiratory tract inflammatory and imm	iunologic conditions	1	0
Hypersensitivity pneumonitis		ı,	U
Lower respiratory tract signs and symptoms		2	0
Hiccups		2	0
Pulmonary pain		3	0
Nasal congestion and inflammations		4.0	0
Nasal congestion		10	0
Nasal disorders NEC		4.4	_
Epistaxis		44	0
Nasal crusting		1	0
Nasal septum deviation		1	0
Paranasal sinus disorders (excl infections an	d neoplasms)		_
Sinus congestion		- 4	0
Parenchymal lung disorders NEC		_	_
Interstitial lung disease		2	0
Pharyngeal disorders (excl infections and ne	oplasms)		
Pharyngeal swelling		10	0
Pharyngeal ulceration		1	0
Tonsillar hypertrophy		2	0
Tonsillar ulcer		1	0
Pleural infections and inflammations			
Pleurisy		1	0
Pneumothorax and pleural effusions NEC			
Pleural effusion		1	0
Pulmonary oedemas			
Pulmonary oedema		1	0
Pulmonary thrombotic and embolic condition	s		
Pulmonary embolism		24	1
Respiratory failures (excl neonatal)			
Respiratory failure		2	1

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
Respiratory disorders espiratory disorders cont'd		
Respiratory signs and symptoms NEC		
Allergic respiratory symptom	1	0
Diaphragmalgia	3	0
Respiratory tract disorders NEC		
Lung disorder	1	0
Respiratory disorder	1	0
Respiratory tract irritation	2	0
Upper respiratory tract signs and symptoms		
Aphonia	3	0
Dry throat	11	0
Dysphonia	5	0
Increased viscosity of upper respiratory secretion	2	0
Nasal discomfort	2	0
Oropharyngeal blistering	3	0
Oropharyngeal pain	87	0
Paranasal sinus discomfort	4	0
Rhinalgia	2	0
Rhinorrhoea	43	0
Sinus pain	18	0
Sneezing	16	0
Throat irritation	8	0
Throat tightness	7	0
Upper-airway cough syndrome	2	0
Yawning	3	0
Respiratory disorders SOC TOTAL	688	2

## Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Earliest Reaction Date: 07-Feb-2018	MedDRA Version: MedDRA 27.0		
Reaction Name		<u>Total</u>	<u>Fatal</u>
Skin disorders			
Acnes			
Acne		3	0
Acne cystic		1	0
Alopecias			
Alopecia		25	0
Alopecia areata		2	0
Lichen planopilaris		1	0
Angioedemas			
Angioedema		20	0
Circumoral oedema		1	0
Apocrine and eccrine gland disorders			
Cold sweat		37	0
Hyperhidrosis		220	0
Miliaria		7	0
Night sweats		44	0
Bullous conditions			
Blister		16	0
Blood blister		3	0
Dermatitis bullous			0
Dermatitis herpetiformis		2 1	0
Erythema multiforme		3	0
Pemphigoid		2	0
Dermal and epidermal conditions NEC		-	U
Acute febrile neutrophilic dermatosis		1	0
Dry skin		20	0
Pain of skin		37	0
Papule		6	0
Scab		1	0
Scar discomfort			0
Scar pain		<u></u>	0
Sensitive skin		21	0
Skin burning sensation		17	0
Skin discolouration		10	0
Skin discolouration Skin disorder		2	0
Skin induration		4	
Skin liquidion Skin lesion		2	0
		4	0
Skin plaque Skin reaction		-	0
		5	
Skin sensitisation		1	0
Skin swelling		2	0
Skin warm		11	0
Skin weeping		1	0
Transient acantholytic dermatosis		1	0
Yellow skin		1	0
Dermatitis and eczema			
Dermatitis		4	0
Dermatitis allergic		8	0
Dermatitis atopic		4	0
Dermatitis contact		4	0
Eczema		7	0
Eczema asteatotic		1	0
Intertrigo		1	0

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedD		
Reaction Name	Total	<u>Fatal</u>
Skin disorders Skin disorders cont'd		
Seborrhoeic dermatitis	1	0
Skin irritation	3	0
Stasis dermatitis	1	0
Dermatitis ascribed to specific agent		
Palmar-plantar erythrodysaesthesia syndrome	1	0
Erythemas		
Érythema	96	0
Exfoliative conditions		
Skin exfoliation	5	0
Granulomatous and deep cutaneous inflammatory conditions		
Granuloma annulare	1	0
Hyperkeratoses		
Palmoplantar keratoderma	10	0
Hypopigmentation disorders		
Skin depigmentation	1	0
Nail and nail bed conditions (excl infections and infestations)		_
Nail disorder	1	0
Nail ridging	1	0
Splinter haemorrhages	1	0
Panniculitides		Ĭ
Erythema nodosum	1	0
Papulosquamous conditions		ľ
Lichen planus	1	0
Parapsoriasis	1	0
Pityriasis rosea	1	Ö
Photosensitivity and photodermatosis conditions	1	
Photosensitivity reaction	3	О
Polymorphic light eruption	1	
Pilar disorders NEC	'	
Hair colour changes	1	0
Hair texture abnormal		1
Piloerection	2 2	0
Trichodynia	1	0
Pruritus NEC	1	
Pruritus	253	О
Psoriatic conditions	255	
Psoriasis Psoriasis	6	0
Purpura and related conditions	0	
Petechiae	۰	o
	8	
Purpura  Rashes, eruptions and exanthems NEC	3	1
	044	
Rash	241	
Rash erythematous	84	
Rash macular	28	
Rash morbilliform	1	0
Rash papular	25	1
Rash pruritic	55	
Rash vesicular	5	C
Rosaceas		
Rosacea	2	0
Skin and subcutaneous tissue ulcerations		_
Skin ulcer	2	1 0

### Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
Skin disorders Skin disorders cont'd		
Skin haemorrhages		
Haemorrhage subcutaneous	2	2 0
Skin vascular conditions NEC		
Angiodermatitis	1	0
Skin vasculitides		
Hypersensitivity vasculitis	1	0
Urticarias		
Idiopathic urticaria	1	0
Urticaria	72	2 0
Urticaria chronic	3	0
Urticaria contact	1	0
Skin disorders SOC TOTAL	1490	ol o

## Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
Social circumstances		
Age related issues		
Menopause	2	0
Disability issues		
Bedridden	1	0
Immobile	1	0
Immobilisation prolonged	1	0
Impaired work ability	2	0
Physical disability	1	0
Sight disability	2	0
Non-occupational and unspecified environmental problems		
Water pollution	1	0
Social issues NEC		
Blood donor	1	0
Tattoo	1	0
Unhealthy lifestyle	1	0
Tobacco use		
Tobacco user	1	0
Social circumstances SOC TOTAL	15	0

### Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
Surgical & medical procedures		
Cardiac therapeutic procedures NEC		
Cardiac operation	1	0
Contraceptive methods female		
Contraception	1	0
External ear therapeutic procedures		
Cerumen removal	1	0
Facial therapeutic procedures		
Face lift	1	0
Gastrointestinal therapeutic procedures NEC		
Prophylaxis of nausea and vomiting	1	0
Immunisations		
COVID-19 immunisation	2	0
Immunisation	8	0
Limb therapeutic procedures		
Limb immobilisation	1	0
Limb operation	1	0
Therapeutic procedures NEC		
Catheter management	1	0
Interchange of vaccine products	3	0
Tumour excision	1	0
Uterine therapeutic procedures		
Endometrial ablation	3	0
Surgical & medical procedures SOC TOTAL	25	sl o

# Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Farliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Earliest Reaction Date: 07-Feb-2018	MedDRA Version: MedDRA 27.0		
Reaction Name	Tota		Fatal
Vascular disorders	7,545		
Aortic aneurysms and dissections		T	
Aortic intramural haematoma		1	0
Aortic embolism and thrombosis			
Aortic embolus		1	0
Arterial infections and inflammations			
Giant cell arteritis		1	0
Bruising, ecchymosis and purpura			
Achenbach syndrome		1	0
Circulatory collapse and shock			
Circulatory collapse		2	0
Haemorrhages NEC			
Haematoma		5	0
Haemorrhage	3	38	0
Internal haemorrhage		1	0
Lymphangiopathies			
Lymphorrhoea		1	0
Lymphoedemas			
Lymphoedema		1	0
Non-site specific embolism and thrombos	ris		
Embolism		2	0
Thrombosis	4	16	0
Venous thrombosis		1	0
Non-site specific necrosis and vascular ir	sufficiency NEC		
Ischaemia		1	0
Peripheral venous disease		3	0
Non-site specific vascular disorders NEC			
Vascular pain		5	0
Vasodilatation		6	0
Vein disorder		1	0
Peripheral embolism and thrombosis			
Blue toe syndrome		4	0
Deep vein thrombosis	2	25	0
Superficial vein thrombosis		1	0
Thrombophlebitis		1	0
Peripheral vascular disorders NEC			
Cyanosis		8	0
Flushing		23	0
Hot flush		3	0
Peripheral vasoconstriction, necrosis and			
Peripheral coldness	3	36	0
Peripheral ischaemia		1	1
Poor peripheral circulation		3	0
Raynaud's phenomenon		6	0
Phlebitis NEC			
Phlebitis		3	0
Site specific vascular disorders NEC			
Pallor	1	10	0
Varicose veins NEC			
Spider vein		2	0
Varicophlebitis		1	0
Varicose vein		4	0
Vascular hypertensive disorders NEC			

## Name: FOI 2024/00093 COVID-19 Vaccine AstraZeneca (Batch 4120Z002) Vaccine Analysis Print

Report Run Date: 24-May-2024 Data Lock Date: 23-May-2024 18:30:03
Earliest Reaction Date: 07-Feb-2018 MedDRA Version: MedDRA 27.0

Reaction Name	Total	Fatal
Vascular disorders Vascular disorders cont'd		
Diastolic hypertension	1	0
Hypertension	29	0
White coat hypertension	3	0
Vascular hypotensive disorders		
Hypotension	12	0
Vasculitides NEC		
Vasculitis	12	0
Vascular disorders SOC TOTAL	365	1
TOTAL REACTIONS FOR DRUG	20650	13
TOTAL REPORTS	5372	
TOTAL FATAL OUTCOME REPORTS		13